Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

Digestive and Liver Disease

Volumn 49, Issue 7, 2017, Pages 731-741

  Viganò, Mauro ^a   Perno, Carlo Federico ^d   Craxì, Antonio ⁱ   Aghemo, Alessio ^a   Alberti, Alfredo ^b   Andreone, Pietro ^c   Andreoni, Massimo ^d   Bonora, Stefano ^e   Brunetto, Maurizia Rossana ^f   Bruno, Raffaele ^g   Bruno, Savino ^h   Calvaruso, Vincenza ⁱ   Caporaso, Nicola ^j   Ceccherini Silberstein, Francesca ^d   Cento, Valeria ^d   Ciancio, Alessia ^e   Colombatto, Piero ^f   Degasperi, Elisabetta ^a   Di Marco, Vito ⁱ   Di Perri, Giovanni ^e   D'offizi, Gianpiero ^k   Fagiuoli, Stefano ^l   Ferrari, Carlo ^m   Gaeta, Giovanni Battista ⁿ   Pellicelli, Adriano ^o   Petta, Salvatore ⁱ   Piovesan, Sara ^b   Puoti, Massimo ^p   Raimondo, Giovanni ^q   Russo, Francesco Paolo ^r   Taliani, Gloria ^s   Trama, Ugo ^t   Villa, Erica ^u   Zignego, Anna Linda ^v   more..

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY HOSPITAL OF PISA   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h HUMANITAS UNIVERSITY   (Italy)

ⁱ UNIVERSITY OF PALERMO   (Italy)

^j UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^k NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^l PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^m Unit of Infectious Diseases and Hepatology   (Italy)

ⁿ SECOND UNIVERSITY OF NAPLES   (Italy)

^o SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^p OSPEDALE NIGUARDA CA GRANDA   (Italy)

^q UNIVERSITY OF MESSINA   (Italy)

^r UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^s SAPIENZA UNIVERSITY OF ROME   (Italy)

^t UOD 08 (Politica del Farmaco) della Regione Campania   (Italy)

^u UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^v UNIVERSITY OF FLORENCE   (Italy)

more..

Author keywords

Antiviral treatment; Cirrhosis; Direct acting antiviral agents; Hepatitis C; RAV; Treatment failure

Indexed keywords

NONSTRUCTURAL PROTEIN 5A INHIBITOR; PEGINTERFERON; ANTIVIRUS AGENT;

ARTICLE; CHRONIC LIVER DISEASE; COMPENSATED LIVER CIRRHOSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG TREATMENT FAILURE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; ITALY; LIVER FIBROSIS; PRIORITY JOURNAL; RETREATMENT; VIRUS LOAD; ADULT; AGED; CHRONIC HEPATITIS C; CLASSIFICATION; COMBINATION DRUG THERAPY; CONSENSUS; DRUG EFFECTS; FIBROSIS; HEPACIVIRUS; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CONSENSUS; DRUG THERAPY, COMBINATION; FIBROSIS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; ITALY; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; VIRAL LOAD; YOUNG ADULT;

EID: 85018677664     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2017.03.027     Document Type: Article

References (62)

1. Webster, D.P., Klenerman, P., Dusheiko, G.M., Hepatitis C. The Lancet 385 (2015), 1124–1135.
2. GBD 2013 Mortality and Causes of Death Collaborators, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet 385 (2015), 117–171.
3. Alter, M.J., Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology 13 (2007), 2436–2441.
4. Messina, J.P., Humphreys, I., Flaxman, A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
5. van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
6. Deterding, K., Hoener zu Siederdissen, C., Port, K., et al. Improvement of liver function parameters in advanced HCV associated liver cirrhosis by IFN-free antiviral therapies. Alimentary Pharmacology Therapeutics 42 (2015), 889–901.
7. Jacobson, I.M., Asselah, T., Nahass, R., et al. A randomized phase 3 trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 weeks compared to Sofosbuvir/Velpatasvir for 12 weeks in DAA-naïve genotype 1–6 HCV infected patients: the POLARIS-2 study. Hepatology, 64(Suppl. S1), 2016 [Abstract LB12].
8. Zeuzem, S., Flamm, S.L., Tong, M., et al. A randomized, controlled, phase 3 trial of Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir/Velpatasvir for 12 weeks in direct-acting antiviral-experienced patients with genotype 1–6 HCV infection: the POLARIS-4 study. Hepatology, 64(Suppl. S1), 2016 [Abstract 109].
9. Zeuzem, S., Feld, J., Wang, S., et al. ENDURANCE-1: a phase 3 evaluation of the efficacy and safety of 8- versus 12-week treatment with Glecaprevir/Pibrentasvir (formerly ABT-493/ABT-530) in HCV genotype 1 infected patients with or without HIV-1 co-infection and without cirrhosis. Hepatology, 64(Suppl. S1), 2016 [Abstract 253].
10. Asselah, T., Hezode, Zadeikis, N., et al. ENDURANCE-4: efficacy and safety of Glecaprevir/Pibrentasvir (Formerly ABT-493/ABT-530) treatment in patients with chronic HCV genotype 4, 5, or 6 infection. Hepatology, 64(Suppl. S1), 2016 [Abstract 114].
11. Kowdley, K.V., Colombo, M., Zadeikis, N., et al. ENDURANCE-2: safety and efficacy of Glecaprevir/Pibrentasvir in hepatitis C virus genotype 2-infected patients without cirrhosis: a randomized, double-blind, placebo-controlled study. Hepatology(Suppl. S1), 2016, 64 [Abstract 73].
12. Wyles, D., Poordad, F., Wang, S., et al. SURVEYOR-II, part 3: efficacy and safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or cirrhosis. Hepatology, 64(Suppl. S1), 2016 [Abstract 113].
13. Gane, E., Lawitz, E., Pugatch, D., et al. EXPEDITION-4: efficacy and safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in patients with renal impairment and chronic hepatitis C virus genotype 1–6 infection. Hepatology, 64(Suppl. S1), 2016 [Abstract LB11].
14. Lawitz, E., Yoshida, E.M., Buti, M., et al. Safety and efficacy of the fixed-dose combination regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2 or 3 infection (Part B of C-CREST-1 & -2). Hepatology, 64(Suppl. S1), 2016 [Abstract 110].
15. Wyles, D., Wedemeyer, H., Reddy, K.R., et al. Safety and efficacy of the fixed-dose combination regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE). Hepatology, 64(Suppl. S1), 2016 [Abstract 193].
16. EASL, Recommendations on treatment of hepatitis C. Journal of Hepatology 66 (2017), 153–194.
17. Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine 370 (2014), 211–221.
18. Poordad, F., Schiff, E.R., Vierling, J.M., et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63 (2016), 1493–1505.
19. Zhou, N., Han, Z., Hartman-Neumann, S., et al. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. Journal of Antimicrobial Chemotherapy 71 (2016), 3495–3505.
20. Mangia, A., Arleo, A., Copetti, M., et al. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver International 36 (2016), 971–976.
21. Cacciola, I., Petta, S., Distefano, M., et al. Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to hepatitis C virus infection: the real-life experience of the Sicily registry. Digestive and Liver Disease, 49S, 2017, e6 [OC-11].
22. Feld, J.J., Jacobson, I.M., Hézode, C., et al. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine 373 (2015), 2599–2607.
23. Foster, G.R., Afdhal, N., Roberts, S.K., et al. Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection. New England Journal of Medicine 373 (2015), 2608–2617.
24. Tacke, F., Günther, R., Buggisch, P., et al. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver International 37 (2017), 205–211.
25. Welzel, T.M., Nelson, D.R., Morelli, G., et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut, 2016 [Epub ahead of print].
26. Curry, M.P., O'Leary, J.G., Bzowej, N., et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. New England Journal of Medicine 373 (2015), 2618–2628.
27. Susser, S., Dietz, J., Barak, M., et al. Prevalence and clinical importance of hepatitis C virus genotype 2 K/1 B chimeras. Journal of Hepatology, 64, 2016, S136.
28. Susser, S., Dietz, J., Vermehren, J., et al. European Ravs database: frequency and characteristics of Ravs in treatment-naïve and DAA-experienced patients. Journal of Hepatology, 64, 2016, S139.
29. AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA recommendations for testing, managing, and treating Hepatitis C [ http://www.hcvguidelines.org].
30. Nelson, D.R., Cooper, J.N., Lalezari, J.P., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
31. McPhee, F., Hernandez, D., Zhou, N., et al. Next-generation sequencing analysis of NS5A and NS5 B minor resistance-associated variants in patients with HCV genotype 3 infection who failed treatment with Daclatasvir plus Sofosbuvir. Journal of Hepatology 64 (2016), S614–S615.
32. Leroy, V., Angus, P., Bronowicki, J.P., et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 63 (2016), 1430–1441.
33. Pasulo, L., Aghemo, A., Quirino, T., et al. Genotype 3 infection in DAA era: reports of a real life Northern Italy Network for viral hepatitis after 2 years by the start. Digestive and Liver Disease, 49S, 2017, e68 [F-47].
34. Pellicelli, A., Messina, V., Tarquini, P., et al. Daclatasvir/sofosbuvir and ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: the CLEO experience. Digestive and Liver Disease, 49S, 2017, e64 [F-39].
35. Hézode, C., Lebray, P., De Ledinghen, V., et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French Early Access Programme. Liver International, 2017 [Epub ahead of print].
36. Foster, G.R., Thompson, A.J., Ruane, P.J., et al. A randomized phase 3 trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 weeks and Sofosbuvir/Velpatasvir for 12 weeks for patients with genotype 3 HCV infection and cirrhosis: the POLARIS-3 study. Hepatology, 64(Suppl. S1), 2016 [Abstract 258].
37. Welzel, T.M., Petersen, J., Herzer, K., et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 65 (2016), 1861–1870.
38. Muir, A.J., Strasser, S., Wang, S., et al. High Svr rates with ABT-493 + ABT-530 co-administered for 8 weeks in non-cirrhotic patients with HCV genotype 3 infection. Journal of Hepatology, 64, 2016, S186.
39. Foster, G.R., Gane, E., Asatryan, A., et al. Endurance-3: a phase 3, randomized, open-label, active-controlled study to compare efficacy and safety of ABT-493/ABT-530 to Sofosbuvir co-administered with Daclatasvir in adults with HCV genotype 3 infection. Journal of Hepatology, 64, 2016, S292.
40. Bourlière, M., Gordon, S.C., Ramji, A., et al. Sofosbuvir/Velpatasvir/Voxilaprevir for 12 weeks as a salvage regimen in NA inhibitor-experienced patients with genotype 1–6 infection: the phase 3 POLARIS-1 study. Hepatology, 64(Suppl. S1), 2016 [Abstract 194].
41. Aragri, M., Di Maio, V.C., Di Paolo, D., et al. In the era of new direct acting antiviral agents HCV sequencing allows the most accurate subtype and genotype assignment. Journal of Hepatology 64 (2016), S419–S420.
42. Di Maio, V.C., Cento, V., Lenci, I., et al. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies. Digestive and Liver Disease 49S (2017), e49–e50 [F-14].
43. Wyles, D., Pockros, P., Morelli, G., et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 61 (2015), 1793–1797.
44. Sullivan, J.C., De Meyer, S., Bartels, D.J., et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clinical Infectious Diseases 57 (2013), 221–229.
45. Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New England Journal of Medicine 370 (2014), 1483–1493.
46. Dvory-Sobol, H., Wyles, D., Ouyang, W., et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. Journal of Hepatology, 62, 2015, S221.
47. Lahser, F., Galloway, A., Hwang, P., et al. Interim analysis of a 3-year follow-up study of NA and NS3 resistance-associated variants (RAVs) after treatment with Grazoprevir-containing regimens in patients with chronic hepatitis C virus (HCV) infection. Hepatology, 64(Suppl. S1), 2016 [Abstract 61].
48. Wyles, D., Dvory-Sobol, H., Svarovskaia, E.S., et al. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. Journal of Hepatology, 2016, 30699–30707 [Epub ahead of print].
49. Poordad, F., Gordon, S.C., Asatryan, A., et al. High efficacy of ABT-493 and ABT-530 in HCV genotype 1-infected patients who have failed direct-acting antiviral-containing regimens: the MAGELLAN-1 study. Journal of Hepatology 64 (2016), S160–S161.
50. Ceccherini Silberstein, F., Di Maio, V.C., Aragri, M., et al. Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology 63 (2016), 1058–1059.
51. Kowdley, K.V., Gordon, S.C., Reddy, K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine 370 (2014), 1879–1888.
52. Zeuzem, S., Ghalib, R., Reddy, K.R., et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and non cirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Annals of Internal Medicine 163 (2015), 1–13.
53. Kwo, P., Gane, E., Peng, C.Y., et al. Efficacy and safety of grazoprevir/elbasvir plus or minus RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE Treatment-Experienced trial. Journal of Hepatology 62 (2015), S674–S675.
54. Zeuzem, S., Mizokami, M., Planko, S., et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. Journal of Hepatology, 2017 [Epub ahead of print].
55. Sarrazin, C., Dvory-Sobol, H., Svarovskaia, E.S., et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with Ledipasvir and Sofosbuvir. Gastroenterology 151 (2016), 501–512.
56. Desnoyer, A., Pospai, D., Lê, M.P., et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. Journal of Hepatology 65 (2016), 40–47.
57. De Nicola, S., Aghemo, A., The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment. Liver International 36 (2016), 791–793.
58. Saxena, V., Koraishy, F.M., Sise, M.E., et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver International 36 (2016), 807–816.
59. Pockros, P.J., Reddy, K.R., Mantry, P.S., et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150 (2016), 1590–1598.
60. Gane, E.J., Solà, R., Cohen, E., et al. RUBY-II: efficacy and safety of a ribavirin-free Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir regimen in patients with severe renal impairment or end-stage renal disease and HCV genotypes 1a or 4 infection. Hepatology, 64(Suppl. S1), 2016 [Abstract 935].
61. Roth, D., Nelson, D.R., Bruchfeld, A., et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. The Lancet 386 (2015), 1537–1545.
62. Craxi, A., Perno, C.F., Viganò, M., et al. From current status to optimization of HCV treatment: recommendations from an expert panel. Digestive and Liver Disease 48 (2016), 995–1005.